These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 18409502

  • 21. [The study of optimal treatment in patients with refractory chronic hepatitis C].
    Chen XY, Zhang YH.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):488-9. PubMed ID: 19912679
    [No Abstract] [Full Text] [Related]

  • 22. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [Abstract] [Full Text] [Related]

  • 23. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
    Biermer M, Berg T.
    Gastroenterology; 2009 Jul; 137(1):390-1. PubMed ID: 19486953
    [No Abstract] [Full Text] [Related]

  • 24. [Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
    Xie Y, Li MH.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):484-6. PubMed ID: 19912677
    [No Abstract] [Full Text] [Related]

  • 25. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I, Rigla M, Torras X, Enríquez J, Corcoy R.
    Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
    [No Abstract] [Full Text] [Related]

  • 26. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [Abstract] [Full Text] [Related]

  • 27. [Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].
    Dou XG.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):486-7. PubMed ID: 19912678
    [No Abstract] [Full Text] [Related]

  • 28. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Aghemo A, Rumi MG, Colombo M.
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
    [Abstract] [Full Text] [Related]

  • 29. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group.
    Antivir Ther; 2007 Oct; 12(4):469-76. PubMed ID: 17668555
    [Abstract] [Full Text] [Related]

  • 30. [Combination therapy for chronic viral hepatitis C].
    Zeuzem S.
    Dtsch Med Wochenschr; 2003 Feb 21; 128(8):370-4. PubMed ID: 12594622
    [No Abstract] [Full Text] [Related]

  • 31. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M, Luznik Z, Stepec S, Popovic P, Snedec N, Poljak M, Stanisavljevic D.
    J Clin Gastroenterol; 2014 Feb 21; 48(5):464-5. PubMed ID: 24275712
    [No Abstract] [Full Text] [Related]

  • 32. Hepatitis C virus therapy to date.
    Foster G, Mathurin P.
    Antivir Ther; 2008 Feb 21; 13 Suppl 1():3-8. PubMed ID: 18432157
    [Abstract] [Full Text] [Related]

  • 33. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M, Pérez Carreras M, Muñoz Gómez R, Castellano Tortajada G.
    Gastroenterol Hepatol; 2011 Oct 21; 34(8):584-5. PubMed ID: 21641684
    [No Abstract] [Full Text] [Related]

  • 34. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G, Gentile R, Ansaldi F, Borro P, Ravetti G, Icardi G, Sumberaz A.
    Panminerva Med; 2009 Jun 21; 51(2):135-6. PubMed ID: 19776716
    [No Abstract] [Full Text] [Related]

  • 35. [Treatment of patients with normal liver aminotransferases].
    González Ballerga E, Levi D, Reggiardo V.
    Acta Gastroenterol Latinoam; 2005 Jun 21; 35 Suppl 1():S50-2. PubMed ID: 20214303
    [No Abstract] [Full Text] [Related]

  • 36. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E, Rizzetto M, Saracco G.
    Hepatology; 1998 Aug 21; 28(2):341-6. PubMed ID: 9695995
    [Abstract] [Full Text] [Related]

  • 37. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC, Chien RN.
    Aliment Pharmacol Ther; 2013 Feb 21; 37(4):492. PubMed ID: 23336679
    [No Abstract] [Full Text] [Related]

  • 38. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
    Patel MR, Mullen MP, Dieterich DT.
    AIDS Read; 2006 Mar 21; 16(3):164, 168-9; discussion 168-9. PubMed ID: 16538956
    [Abstract] [Full Text] [Related]

  • 39. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N, Aykin N, Demirdal T, Cevik F.
    Eur J Dermatol; 2006 Mar 21; 16(5):579-80. PubMed ID: 17101483
    [No Abstract] [Full Text] [Related]

  • 40. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M.
    N Engl J Med; 2007 Mar 22; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.